Combination of Gemcitabine and Paclitaxel is a Favorable Option for Patients with Advanced or Metastatic Urothelial Carcinoma Previously Treated with Cisplatin-based Chemotherapy

摘要: Objective: To evaluate the efficacy and toxicity of a gemcitabine paclitaxel regimen for patients with advanced urothelial carcinoma who had previously been treated methotrexate, vinblastine, doxorubicin cisplatin chemotherapy, to determine prognostic factors survival in second-line chemotherapy. Methods: From June 2005 April 2010, 24 eligible chemotherapy were enrolled this study. Patients received 200 mg/m 2 on Day 1 1000 Days 1, 8 15. The was repeated every 3 weeks. evaluated two cycles by imaging Results: Ten (42%) major response regimen, including (8%) complete response. Median time median progression-free 12.4 6.1 months, respectively. Good performance status first-line treatment significant predictors overall survival. Grade or 4 neutropenia occurred 16 (67%), but there no severe infections. There treatment-related deaths. Conclusions: Gemcitabine favorable benefit safety profiles, is recommended as potential metastatic